t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia-Reference-Cited by-同舟云学术

t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia

Published:2009-03-26 Issue:4 Volume:89 Page:508-512
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Denčić-Fekete Marija,Đorđević Vesna,Storlazzi Clelia Tiziana,Janković Gradimir,Bogdanović Andrija,Jovanović Jelica,Rocchi Mariano,Todorić-Živanović Biljana,Strnad Milica,Gotić Mirjana

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-009-0275-8.pdf

Reference25 articles.

1. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian H. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–72. doi: 10.1056/NEJM199907153410306 .

2. Deininger M, Goldman J, Melo J. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–56.

3. Cullen J, Richards J, Dickinson H, Carter C, Swirsky M, Owen G. Development and progression of a Philadelphia-chromosome-negative acute myelocytic leukemia clone in a patient with Philadelphia chromosome-positive chronic myelocytic leukemia. Cancer Genet Cytogenet. 2004;148:170–3. doi: 10.1016/S0165-4608(03)00277-2 .

4. Bumm T, Muller C, Al-Ali K, et al. Emergence of clonal cytogenetic abnormalities in Ph− cells in some CML patients in remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood. 2003;101:1941–9. doi: 10.1182/blood-2002-07-2053 .

5. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003;98:1905–11. doi: 10.1002/cncr.11729 .

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Several different cytogenetic clones arising during treatment of Philadelphia positive chronic myeloid leukemia with tyrosine kinase inhibitors lead to the progression into Philadelphia negative acute myeloid leukemia;Vojnosanitetski pregled;2021